AU2005222909B2 - Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide - Google Patents
Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide Download PDFInfo
- Publication number
- AU2005222909B2 AU2005222909B2 AU2005222909A AU2005222909A AU2005222909B2 AU 2005222909 B2 AU2005222909 B2 AU 2005222909B2 AU 2005222909 A AU2005222909 A AU 2005222909A AU 2005222909 A AU2005222909 A AU 2005222909A AU 2005222909 B2 AU2005222909 B2 AU 2005222909B2
- Authority
- AU
- Australia
- Prior art keywords
- hiv
- antigen
- immunomodulatory oligonucleotide
- immunogen
- depleted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55287104P | 2004-03-12 | 2004-03-12 | |
| US60/552,871 | 2004-03-12 | ||
| PCT/US2005/008238 WO2005089231A2 (en) | 2004-03-12 | 2005-03-11 | Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005222909A1 AU2005222909A1 (en) | 2005-09-29 |
| AU2005222909B2 true AU2005222909B2 (en) | 2010-03-11 |
Family
ID=34994209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005222909A Ceased AU2005222909B2 (en) | 2004-03-12 | 2005-03-11 | Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050266015A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1729802A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008500963A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101217973A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005222909B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2557443A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005089231A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| NZ540098A (en) | 2002-10-29 | 2008-09-26 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
| HRP20181039T1 (hr) * | 2010-05-28 | 2018-08-24 | Zoetis Belgium S.A. | Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040198685A1 (en) * | 2003-01-16 | 2004-10-07 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
| OA13246A (en) * | 2003-08-28 | 2007-01-31 | Immune Response Corp Inc | Immunogenic HIV Compositions and related methods. |
-
2005
- 2005-03-11 CA CA002557443A patent/CA2557443A1/en not_active Abandoned
- 2005-03-11 AU AU2005222909A patent/AU2005222909B2/en not_active Ceased
- 2005-03-11 JP JP2007503063A patent/JP2008500963A/ja active Pending
- 2005-03-11 WO PCT/US2005/008238 patent/WO2005089231A2/en not_active Ceased
- 2005-03-11 EP EP05725427A patent/EP1729802A4/en not_active Withdrawn
- 2005-03-11 US US11/078,654 patent/US20050266015A1/en not_active Abandoned
- 2005-03-11 CN CNA2005800079845A patent/CN101217973A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040198685A1 (en) * | 2003-01-16 | 2004-10-07 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
Non-Patent Citations (2)
| Title |
|---|
| Horner, A.A. The Journal of Immunology, 2001, Vol.167, pages 1584-1591 * |
| Lisawan, A., Vaccine, 1996, Vol.16, No.213, pages 142-149 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2557443A1 (en) | 2005-09-29 |
| AU2005222909A1 (en) | 2005-09-29 |
| EP1729802A2 (en) | 2006-12-13 |
| JP2008500963A (ja) | 2008-01-17 |
| EP1729802A4 (en) | 2009-12-16 |
| US20050266015A1 (en) | 2005-12-01 |
| WO2005089231A3 (en) | 2007-12-06 |
| WO2005089231A2 (en) | 2005-09-29 |
| CN101217973A (zh) | 2008-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2372960C (en) | Hiv immunogenic compositions and methods | |
| US6737066B1 (en) | HIV immunogenic compositions and methods | |
| Kim et al. | In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen | |
| Sjölander et al. | Immune responses to ISCOM® formulations in animal and primate models | |
| Borsutzky et al. | Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant | |
| Fast et al. | Human trials of experimental AIDS vaccines | |
| Kommareddy et al. | MF59: A safe and potent adjuvant for human use | |
| Tsuji et al. | HIV‐1‐specific cell‐mediated immunity is enhanced by co‐inoculation of TCA3 expression plasmid with DNA vaccine | |
| Newman et al. | Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates | |
| US20050266015A1 (en) | Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide | |
| US20030044428A1 (en) | Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment | |
| RU2396346C2 (ru) | Применение инактивированного цельного вируса совместимого субтипа для получения бесклеточной вакцины и способ лечения вич-инфекции | |
| US20070253979A1 (en) | Immunogenic Hiv Compositions and Related Methods | |
| US20080026448A1 (en) | Production of HIV | |
| HK1114789A (en) | Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide | |
| WO2024173143A2 (en) | Vaccines incorporating hiv th/ctl epitope peptides to prevent and treat patients with hiv infection and aids | |
| KR20070019635A (ko) | 면역원성 hiv 조성물 및 이와 관련된 방법 | |
| AU2011310643A1 (en) | Vaccine | |
| Rodríguez-Alonso et al. | IMS 4112 and VLP of HBV as Th1 Adjuvants for a Recombinant Protein of HIV-1 | |
| Poonam | Induction of strong cellular immune responses in the gut mucosa against HIV-1 using a combination vaccine of recombinant Clostridium perfringens and HIV-1 virus like particles | |
| ZA200108559B (en) | HIV immunogenic compositions and methods. | |
| MXPA01010784A (en) | Hiv immunogenic compositions and methods | |
| WO2003082908A2 (en) | Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: THE IMMUNE RESPONSE CORPORATION; IDERA PHARMACEUTI Free format text: FORMER APPLICANT(S): THE IMMUNE RESPONSE CORPORATION; HYBRIDON, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |